ECM
FATE icon

Endurant Capital Management’s Fate Therapeutics FATE Stock Holding History

Endurant Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-71,640
Closed -$1.77M – 57
2022
Q2 		$1.77M Buy
71,640
+11,908
+20% +$329K 0.62% 36
2022
Q1 		$2.32M Buy
59,732
+22,407
+60% +$868K 0.61% 36
2021
Q4 		$2.18M Buy
+37,325
New +$2.12M 0.53% 39
2021
Q3 		– Sell
-51,031
Closed -$4.43M – 56
2021
Q2 		$4.43M Buy
51,031
+37,599
+280% +$3.03M 1.22% 32
2021
Q1 		$1.11M Sell
13,432
-53,153
-80% -$5.09M 0.29% 55
2020
Q4 		$6.05M Buy
66,585
+10,375
+18% +$644K 2.18% 15
2020
Q3 		$2.25M Sell
56,210
-4,682
-8% -$163K 0.66% 40
2020
Q2 		$2.09M Buy
60,892
+20,160
+49% +$601K 0.11% 40
2020
Q1 		$905K Sell
40,732
-94,290
-70% -$2.38M 0.41% 37
2019
Q4 		$2.64M Sell
135,022
-31,760
-19% -$504K 0.83% 31
2019
Q3 		$2.59M Buy
+166,782
New +$3.2M 0.93% 24
2018
Q4 		– Sell
-204,333
Closed -$3.33M – 61
2018
Q3 		$3.33M Buy
204,333
+121,761
+147% +$1.44M 1.48% 26
2018
Q2 		$936K Sell
82,572
-72,772
-47% -$802K 0.41% 46
2018
Q1 		$1.52M Sell
155,344
-401,335
-72% -$3.84M 0.57% 43
2017
Q4 		$3.4M Buy
556,679
+283,979
+104% +$1.27M 1.04% 37
2017
Q3 		$1.08M Buy
+272,700
New +$927K 0.33% 67

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Endurant Capital Management's FATE Position: Q3 2022 in Review

Endurant Capital Management sold out of Fate Therapeutics (FATE) in Q3 2022, closing a stake of 71,640 shares — an estimated $1.77M sold.

Endurant Capital Management first reported a position in FATE in Q3 2017 and held it in 16 quarters. The position peaked at $6.05M in Q4 2020. 239 funds tracked by Wall St. Rank hold FATE as of Q3 2022.

  • Endurant Capital Management reported no remaining Fate Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Endurant Capital Management sold 71,640 Fate Therapeutics shares in Q3 2022, an estimated $1.77M.
  • Endurant Capital Management first reported a position in Fate Therapeutics in Q3 2017 and held it in 16 quarters.
  • Endurant Capital Management's Fate Therapeutics position peaked at $6.05M in Q4 2020.
  • 239 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2022.

Based on Endurant Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.